Abstract

In Parkinson’s disease and other synucleinopathies, the elevation of α-synuclein phosphorylated at Serine129 (pS129) is a widely cited marker of pathology. However, the physiological role for pS129 has remained undefined. Here we use multiple approaches to show for the first time that pS129 functions as a physiological regulator of neuronal activity. Neuronal activity triggers a sustained increase of pS129 in cultured neurons (200% within 4 h). In accord, brain pS129 is elevated in environmentally enriched mice exhibiting enhanced long-term potentiation. Activity-dependent α-synuclein phosphorylation is S129-specific, reversible, confers no cytotoxicity, and accumulates at synapsin-containing presynaptic boutons. Mechanistically, our findings are consistent with a model in which neuronal stimulation enhances Plk2 kinase activity via a calcium/calcineurin pathway to counteract PP2A phosphatase activity for efficient phosphorylation of membrane-bound α-synuclein. Patch clamping of rat SNCA−/− neurons expressing exogenous wild-type or phospho-incompetent (S129A) α-synuclein suggests that pS129 fine-tunes the balance between excitatory and inhibitory neuronal currents. Consistently, our novel S129A knock-in (S129AKI) mice exhibit impaired hippocampal plasticity. The discovery of a key physiological function for pS129 has implications for understanding the role of α-synuclein in neurotransmission and adds nuance to the interpretation of pS129 as a synucleinopathy biomarker.

Details

Title
Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity
Author
Ramalingam, Nagendran 1   VIAFID ORCID Logo  ; Jin, Shan-Xue 1 ; Moors, Tim E. 1 ; Fonseca-Ornelas, Luis 1   VIAFID ORCID Logo  ; Shimanaka, Kazuma 1 ; Lei, Shi 2 ; Cam, Hugh P. 2 ; Watson, Aurelia Hays 3 ; Brontesi, Lisa 1 ; Ding, Lai 1 ; Hacibaloglu, Dinc Yasat 1 ; Jiang, Haiyang 1   VIAFID ORCID Logo  ; Choi, Se Joon 4 ; Kanter, Ellen 4 ; Liu, Lei 1   VIAFID ORCID Logo  ; Bartels, Tim 3 ; Nuber, Silke 1 ; Sulzer, David 5   VIAFID ORCID Logo  ; Mosharov, Eugene V. 6   VIAFID ORCID Logo  ; Chen, Weisheng V. 7 ; Li, Shaomin 1   VIAFID ORCID Logo  ; Selkoe, Dennis J. 1   VIAFID ORCID Logo  ; Dettmer, Ulf 1   VIAFID ORCID Logo 

 Brigham and Women’s Hospital and Harvard Medical School, Ann Romney Center for Neurologic Diseases, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Leveragen, Inc., Worcester, USA (GRID:grid.38142.3c) 
 University College London, UK Dementia Research Institute, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201) 
 New York State Psychiatric Institute, Research Foundation for Mental Hygiene, Division of Molecular Therapeutics, New York, USA (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112) 
 New York State Psychiatric Institute, Research Foundation for Mental Hygiene, Division of Molecular Therapeutics, New York, USA (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112); Columbia University Medical Center, Departments of Neurology and Psychiatry, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Medical Center, Department of Molecular Therapeutics and Pharmacology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675) 
 New York State Psychiatric Institute, Research Foundation for Mental Hygiene, Division of Molecular Therapeutics, New York, USA (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112); Columbia University Medical Center, Departments of Neurology and Psychiatry, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675) 
 Leveragen, Inc., Worcester, USA (GRID:grid.239585.0) 
Pages
4
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
23738057
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2765887077
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.